Indications: Regorafenib is a kinase inhibitor that is indicated: .For the treatment of metastatic colorectal cancer (CRC) after disease progression on or intolerance to fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy. .For the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) after disease progression on or intolerance to prior treatment with imatinib and sunitinib. .For the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib